You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic melanoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8 Trial in

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Unresectable Melanoma, Metastatic Melanoma, Stage III NSCLC Trial in Louisville, New York (IOV-4001)

Recruiting
  • Unresectable Melanoma
  • +3 more
  • IOV-4001
  • Louisville, Kentucky
  • +2 more
Nov 21, 2022

Unresectable Melanoma, Metastatic Melanoma Trial in Orlando, Louisville, New York (Lifileucel)

Available
  • Unresectable Melanoma
  • Metastatic Melanoma
  • Lifileucel
  • Orlando, Florida
  • +2 more
Jul 19, 2022

Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +3 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Jan 3, 2023

Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

Recruiting
  • Metastatic Melanoma
  • BRAF Gene Mutation
  • Nilotinib 100mg
  • +5 more
  • Lexington, Kentucky
    Markey Cancer Center
Jul 22, 2022

Melanoma Trial in Houston (APX005M, Pembrolizumab)

Recruiting
  • Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 22, 2022

Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (GSK2636771, Pembrolizumab)

Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 22, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Monitoring T Cell Responses in Melanoma, Lung and Other Cancer

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +9 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Oct 4, 2023

Melanoma Trial (Blood samples, Skin biopsy)

Not yet recruiting
  • Melanoma
  • Blood samples
  • Skin biopsy
  • (no location specified)
Oct 3, 2022

Locally Advanced or Metastatic Melanoma Trial (CBL0137, Ipilimumab, Nivolumab)

Not yet recruiting
  • Locally Advanced or Metastatic Melanoma
  • (no location specified)
Aug 10, 2022

Generation ofArtificial Intelligence Algorithm Based on Analysis

Not yet recruiting
  • Metastatic Melanoma
  • Photo
  • (no location specified)
May 3, 2023

Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Immune checkpoint inhibitor
  • Ljubljana, Slovenia
    Institute of Oncology Ljubljana
May 17, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Anti-PD-L1 Monoclonal Antibody IMC-001
  • Punch Biopsy
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma Trial in Boston

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Boston, Massachusetts
  • +2 more
Sep 17, 2022

Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy Trial in Leiden (Nivolumab & Tumor Infiltrating Lymphocytes

Recruiting
  • Toxicity, Drug
  • +2 more
  • Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
  • Leiden, Netherlands
    Leiden University Medical Center
Aug 16, 2022

Metastatic Melanoma Trial in Boston (Pembrolizumab, Infliximab, Placebo)

Recruiting
  • Metastatic Melanoma
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Apr 6, 2022

Melanoma, BRAF V600 Mutation, Unresectable Melanoma Trial in Rennes (Binimetinib Oral Tablet)

Completed
  • Melanoma
  • +3 more
  • Binimetinib Oral Tablet
  • Rennes, France
    Biotrial
Mar 31, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial in

Not yet recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +3 more
  • Biospecimen Collection
  • +8 more
  • Kansas City, Kansas
    University of Kansas Cancer Center
Nov 27, 2023

Metastatic Melanoma Trial in New Haven (Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab)

Terminated
  • Metastatic Melanoma
  • Tumor Infiltrating Lymphocytes
  • Nivolumab and Ipilimumab
  • New Haven, Connecticut
    Yale New Haven Hospital
Jul 20, 2022

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023

Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab

Recruiting
  • Unresectable Melanoma
  • +3 more
  • Sargramostim (GM-CSF)
  • Pembrolizumab (anti-PD-1)
  • Boston, Massachusetts
  • +1 more
Jul 6, 2022

Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)

Not yet recruiting
  • Malignant Melanoma
  • +4 more
  • (no location specified)
Mar 31, 2022

Advanced Glioblastoma, Metastatic Melanoma in the CNS, MGMT-Unmethylated Glioblastoma Trial in Ramat Gan (Crizanlizumab-Tmca 10

Not yet recruiting
  • Advanced Glioblastoma
  • +2 more
  • Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
  • Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
  • Ramat Gan, Israel
    Sheba medical center
Jun 11, 2023